

REVIEW

[View Article Online](#)
[View Journal](#) | [View Issue](#)

Cite this: *J. Mater. Chem. B*, 2025, 13, 4059

Oral mucosa: anti-inflammatory function, mechanisms, and applications

Yani Chen,[†] Bicong Gao,[†] Wenjin Cai, Junhong Lai, Kaichen Lai* and Ying Wang *

Large soft tissue injuries require several weeks to heal and frequently leave fibrotic scars that can negatively impact tissue function. However, the applicability of traditional skin and mucous membrane transplantation for the treatment of lesions in the ocular surface and urethra is limited owing to the unique locations and functions of these tissues. Oral mucosa has been widely used in the repair of such injuries owing to its reduced propensity for inducing an inflammatory response, angiogenesis, and scarring. Enhancing chronic wound healing while avoiding scar formation requires a broader understanding of the cellular and molecular pathways that drive wound repair in the oral mucosa. This review integrates current knowledge on the mechanisms underlying the resistance of the oral mucosa to inflammation and its application as a graft material, highlighting its challenges and potential advancements. The aim of this review is to offer insights into future therapeutic strategies for wound healing and related conditions.

Received 24th December 2024,
Accepted 25th February 2025

DOI: 10.1039/d4tb02845g

rsc.li/materials-b

Introduction

Following soft tissue damage, wound contraction and cell growth drive wound closure. While minor wounds heal within a few days, larger tissue trauma typically requires several weeks to heal and can leave fibrous scars that impair tissue function.¹ Improper wound management can further complicate healing, leading to chronic wounds that cause significant physical and psychological distress to affected individuals, as well as impose substantial economic and social burdens on their families and healthcare systems. This underscores the need for the development of therapeutic strategies that promote efficient and scar-free healing.

Current approaches to repairing soft tissue defects include tissue transplantation, biomaterial implantation, and tissue engineering strategies for tissue reconstruction. Autologous skin grafts, commonly used as a repair material, often exhibit limitations such as mucosal metaplasia, mismatches in color and texture compared to surrounding tissues, and scar hyperplasia. In contrast, the oral mucosa, a non-keratinized squamous epithelium, offers several unique advantages, including abundant availability, ease of harvest, rapid donor site healing, excellent regenerative potential, and the ability to adapt to

different epithelial environments.² These properties, combined with the ability to accelerate healing, minimize scarring, and resist inflammation, make oral mucosa an increasingly attractive option as a biomaterial for regenerative medicine.

Oral mucosa and related biomimetic materials have demonstrated significant potential in enhancing wound healing in various tissues. Clinically, they have been successfully applied for diverse purposes, including accelerating skin wound healing with minimal scarring,³ urethral reconstruction and stricture repair,^{4–6} eyelid^{7–10} and corneal reconstruction,^{11–14} and the treatment of tracheal defects. Notably, oral mucosal wounds exhibit faster and scarless healing compared to cutaneous wounds,^{15–18} a phenomenon closely linked to the rapid and well-regulated resolution of inflammatory responses.¹⁹ This unique healing capability positions the oral mucosa as a valuable model for investigating scar-free tissue regeneration.

This review explores the mechanisms involved in the ability of the oral mucosa to resist inflammation, contrasting them with those of other mucosal linings during wound healing. We focus on the inflammatory processes in four key oral mucosae—gingival mucosa, hard palatal mucosa, buccal mucosa, and tongue lateral mucosa. Precise immune regulation is critical for achieving low-inflammation, scar-free, and rapid healing in oral mucosal wounds. As summarized in Table 1, recent research has identified key mechanisms and pathways involved in the anti-inflammatory and regenerative properties of the oral mucosa, providing a foundation for further investigation. Leveraging the anti-inflammatory properties of the oral mucosa, cellular therapies and bioengineering approaches are being integrated to develop regenerative

Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province, Hangzhou 310000, P. R. China.

E-mail: laikaichen@zju.edu.cn, 7314032@zju.edu.cn

[†] These co-first authors contributed equally to this work.



Table 1 Relevant research involving mechanisms

Oral mucosa	Species	Study design	Key findings	Ref.
Tongue lateral mucosa	Mice	Animal experiment	Oral wounds demonstrate decreased levels of TGF- β 1 by contrast to dermal wounds, accompanied by an increase in the ratio of TGF- β 3 to - β 1.	20
Tongue lateral mucosa	Mice	Animal experiment	Dermal and mucosal keratinocytes have different modulation pathways that contribute to variable responses to injury sites.	21
Gingiva	Human	Animal experiment	Higher levels of inflammation in places with periodontal destruction are related to increased microbial load.	22
—	Mice, human	Animal experiment	Serum and glucocorticoid-regulated kinase 1 (<i>SGK1</i>) maintains the expression of tumor necrosis factor receptor-associated factor 3 (<i>TRAF3</i>), which inhibits the inflammatory response induced by gingival porphyria.	23
Gingiva, oral mucosa	Human	Cell experiment	Inflammatory stimuli priming macrophages stimulate the secretion of active TGF β , leading to autophagy and sustained engagement of myofibroblasts, causing scarring.	24
Lining mucosa, masticatory mucosa	Mice	Animal experiment	Fine-tuning B7-H1 expression in keratinocytes is critical for mucosal defense against disease.	25
Gingiva	Mice, human	Cell experiment	Mechanical injury induces IL-6 in epithelial cells, influencing T-cell function and increasing Th17 cells.	26
Gingiva, buccal mucosa, palatal mucosa, tongue mucosa	Mice	Animal experiment	A high number of Foxp3+ regulatory T cells keep the oral mucosa silent.	27
Buccal mucosa	Mice, human	Clinical study + Cell experiment	With less differentiation and a more persistent inflammatory response, transcriptional circuits located in oral mucosa help wounds heal more quickly.	19
Palatal mucosa	Mice	Animal experiment + Bioinformatic analysis	The oral mucosa has a more complex and inherent biological response than the skin, which accelerates repair for being “preactivated”.	15
Gingiva	Human	Cell experiment	Human saliva promotes wound closure and inflammation in the mouth and skin.	28
Palatal mucosa	Mice	Animal experiment	Since the mucosa is “preactivated,” a substantial alteration in gene expression is not necessary for the healing process to occur.	29
Gingiva, palatal mucosa, tongue mucosa	Mice, human	Animal experiment + Cell experiment	In reaction to damage and inflammatory stimulation, human skin keratinocytes and oral keratinocytes express specific TJ genes differentially.	30
Palatal mucosa	Human	Clinical study + Bioinformatic analysis	The absence of scarless healing in hard palate and gingival wounds is explained by the lack of fibrillar marker expression and autophagy activation.	16
Gingiva, buccal mucosa	Human	Cell experiment	The mesenchymal compartment may serve a previously unrecognized function in immune reactivity, oral homeostasis, and pathogenesis.	31
Gingiva	Mice	Animal experiment	<i>SGK1</i> inhibits the toll-like receptors (TLR)-mediated immune response, which increases inflammation by activating <i>TAK1</i> and NF- κ B in LPS-stimulated immune cells.	32
Cell line of oral squamous cell carcinoma	Human	Animal experiment	Human oral epithelial cells inhibit T-cell function by secreting prostaglandin E2, which can be evaded when under attack.	33
Oral mucosa	Mice	Animal experiment	Regulatory T cell treatment is efficient in reducing oral mucosal inflammation in mice.	34
Buccal mucosa, human oral keratinocytes	Mice	Animal experiment + Cell experiment	Mediator complex subunit 1 (<i>MED1</i>) ablation enhances oral wound healing <i>via</i> an upregulation of keratinocyte proliferation and mobility.	35
Tongue lateral mucosa	Mice, human	Animal experiment + Cell experiment	Signal transducer and activator of transcription 3 (<i>STAT3</i>)-activated small proline rich protein 1B ⁺ (<i>SPRR1B</i> ⁺) keratinocytes are upregulated in wound healing-related gene clusters, preparing the oral mucosa for rapid healing.	36

treatments that reduce scarring in other tissues. However, the specific mechanisms underlying the inflammation-modulatory and barrier-protective properties of the oral mucosa remain incompletely understood. Recent studies on the cellular and molecular pathways governing oral mucosal inflammation have revealed the roles played by cytokines and alterations in gene expression patterns in this process. Nevertheless, a more comprehensive understanding of these mechanisms is necessary to significantly enhance the safety, efficacy, and applicability of oral mucosa in tissue regeneration, paving the way for innovative therapeutic applications.

In this review, we further highlight the interdisciplinary nature of this research, bridging medicine, materials science, and chemistry, aiming to provide insights into the potential of the oral mucosa as a biomaterial for tissue engineering.

We also discuss the challenges and opportunities in scaling up the production of oral mucosa-based grafts and their translation into clinical practice. Ultimately, this review seeks to advance the field by identifying key research directions that will enable the development of innovative therapies for wound healing and tissue regeneration.

Anti-inflammatory mechanisms in different oral mucosae

Gingival mucosa

Following histamine-induced disruption of tight junction protein-encoding genes, oral keratinocytes exhibit superior barrier function compared with skin keratinocytes, as highlighted in Fig. 1,






Fig. 1 Comparative analysis of the structure and function of different oral mucosae. Differences in gene expression and structure underlie the functional differences between different oral mucosae. *CSF3*, *CXCL1*, *CXCL2*, and *CXCL8*, which are specific to neutrophil recruitment, are the most highly expressed genes in the gingival mucosa. A range of molecules, including *hsa-miR-223*, *hsa-miR-21*, *hsa-miR-132*, *hsa-miR-146b*, *hsa-miR-124-3p*, *IL-33*, and *SERPINB1*, are highly regulated in gingival tissue. *CLDN8* is highly expressed in the palatal mucosa at baseline. *SOX2* in oral keratinocytes and key miRNAs such as *miR-34a-5p* and *miR-335-5p* are the most important factors in the buccal mucosa. Site-specific changes in TGF- β 1 levels and the TGF- β 3/- β 1 ratio impact wound healing in lateral tongue mucosa. Created in BioRender. Cai, W. (2025) <https://BioRender.com/x23n962>.

which was hypothesized to result from alterations in tight junction protein levels.³⁰ Unlike other barrier sites, in the gingiva, T-helper 17 (Th17) cells are activated by physiological mechanical injury in the absence of microbial colonization^{37,38} and accumulate in an interleukin-6 (IL-6)-dependent manner.³⁹ This accumulation leads to enhanced secretion of IL-17, a key mediator of barrier-protective responses, such as those associated with antimicrobial defenses. Additionally, due to mastication²⁶ and commensal microbiota activity,^{22,40,41} the expression of genes encoding pro-inflammatory and antimicrobial proteins, such as IL-1 β , secretory leukocyte peptidase inhibitor (SLPI), and S100 calcium-binding protein A8/A9 complex (S100A8/9), is also elevated in the gingiva following injury, particularly in specific clusters of epithelial cells.

The gingival mucosa has unique immune wiring and harbors a stromal cell population in which multiple immune-related pathways and the most upregulated genes, including colony-stimulating factor 3 (*CSF3*), C-X-C motif chemokine ligand 1

(*CXCL1*), C-X-C motif chemokine ligand 2 (*CXCL2*), and C-X-C motif chemokine ligand 8 (*CXCL8*), are primarily associated with neutrophil recruitment. Serum- and glucocorticoid-regulated kinase 1 (*SGK1*) inhibits the *Porphyromonas gingivalis*-induced inflammatory response by maintaining the expression levels of tumor necrosis factor receptor-associated factor 3 (*TRAF3*), the loss of which significantly increases the production of pro-inflammatory cytokines such as tumor necrosis factor (TNF), IL-6, IL-1, and IL-8 in *Porphyromonas gingivalis*-stimulated innate immune cells.^{42,43} Additionally, *SGK1* was reported to be a negative regulator of the Toll-like receptor (TLR)-mediated immune response, whose inhibition heightens the inflammatory response by upregulating the activity of transforming growth factor beta (TGF- β)-activated protein kinase 1 (*TAK1*), which, in turn, heightens that of nuclear factor kappa-B (NF- κ B) in lipopolysaccharide (LPS)-stimulated innate immune cells.³²

Following damage to oral mucosa, wound healing does not promote autophagy in the attached gingiva. Consequently, no



myofibroblast differentiation or collagen deposition is observed. Meanwhile, the inflammatory stimulation of activated macrophages boosts the secretion of activated TGF, which further enhances autophagy and aids in prolonging myofibroblast activation.⁴⁴

Palatal mucosa

The transcriptional changes occurring in skin were found to be more pronounced than those observed in the palate during the wound-healing process.⁴⁵ An integrated investigation¹⁶ of mRNA/miRNA expression during human oral wound healing indicated that *hsa-miR-223* (regulates neutrophil replenishment⁴⁶ and macrophage function,⁴⁷), *hsa-miR-21*, *hsa-miR-132* (enhances re-epithelialization, promotes wound closure, and lowers inflammation⁴⁸), *hsa-miR-146b*, *hsa-miR-124-3p*, IL-33 (a cytokine crucial for the resolution of inflammation⁴⁹), and serpin family b member 1 (*SERPINB1*; inhibits neutrophil serine proteases and inflammatory caspases) were highly regulated in healing palatal tissue.

At the baseline, claudin 8 (*CLDN8*), a tight junction gene that promotes cancer cell migration and proliferation,⁵⁰ was highly expressed in palatal mucosa, whereas *CLDN1* was markedly upregulated in skin. This suggests that different tight junction genes are involved in barrier property maintenance in palatal and cutaneous epithelia.³⁰

Furthermore, PIWI-interacting RNA (piRNA) and P-element-induced wimpy testis (*PIWI*) genes (encoding obligate piRNA binding partners) were noted to be highly expressed in both skin and oral mucosal epithelium during wound healing.⁵¹ Approximately twice as many protein-coding and miRNA genes were upregulated in skin wounds at rest and during healing compared to that in mucosal wounds,¹⁵ suggesting that site-specific healing responses might be impacted by differential PIWI-piRNA complex regulation.⁵²

A human study revealed that scarless healing in hard palatal and gingival wounds could be explained by the lack of fibrillar marker expression and autophagy activation.⁵³ Substantial changes in the mRNA expression levels of key genes were also observed in palatal and gingival tissue following injury. Highly differentially expressed genes included those involved in scar development (ras-related C3 botulinum toxin substrate 1 [*RAC1*], *SERPINE1*, and tissue inhibitor of metalloproteinase 1 [*TIMP1*]), myofibroblast differentiation (*CDH1*, integrin alpha 4 [*ITGA4*], and integrin beta 5 [*ITGB5*]), and inflammation (IL6 and *CXCL1*).

Buccal mucosa

Wound-activated transcriptional networks are already present in the oral mucosa at a basal state. They enhance antimicrobial defenses and immune responses, allowing the oral mucosa to rapidly control and limit the inflammatory response, resulting in the quick relief of inflammation and the promotion of scarless wound healing.¹⁹ In comparison, during the skin healing process, the immune response is overstimulated, culminating in chronic inflammatory responses and scarring.⁵⁴

Iglesias-Bartolome *et al.*¹⁹ demonstrated that the transcription factor SRY-box containing gene 2 (*SOX2*) plays a key role during healing in oral keratinocytes, regulating a network of genes associated with immune and defense responses.¹⁹ Meanwhile, Meng *et al.* revealed that *MED1* ablation promotes oral wound healing by increasing keratinocyte proliferation and mobility.³⁵

Tongue lateral mucosa

Schrementi reported that site-specific variations in TGF- β 1 influence oral wound healing. Compared to cutaneous wounds, oral wounds exhibit a substantially higher TGF- β 3/ β 1 ratio and lower TGF- β 1 levels.²⁰ Additionally, TGF- β 1 is produced by inflammatory cells drawn to the wound site,⁵⁵ increasing synthesis and engagement throughout wound healing *via* auto-crine and paracrine feedback loops.⁵⁶ Xuanyuan *et al.* identified a STAT3-activated *SPRR1B*⁺ keratinocyte subpopulation that was highly enriched for wound healing-associated genes. This subpopulation was shown to prime the oral mucosa for rapid wound healing *via* STAT3 activation.³⁶

Masticatory mucosa and lining mucosa

The mechanisms that maintain masticatory mucosal homeostasis comprise two stages. First, at approximately 3–4 weeks postnatally, the oral microbiota stimulates growth arrest-specific 6 (*GAS6*) expression in the oral epithelium through the activation of TLR2/4 expression, which downregulates pro-inflammatory cytokine secretion and free radical formation, thereby limiting microbiota-mediated epithelial cell activation. In addition, *GAS6* stimulates the differentiation of T regulatory (Treg) cells, but not Th17 cells, by regulating IL-6 expression in dendritic cells. In Fig. 2, the key anti-inflammatory mechanisms in the oral mucosa are depicted in chronological order, highlighting the temporal progression of events that contribute to its unique healing properties.

When the masticatory mucosa is exposed to extended external stimuli³⁸ such as mastication, epithelial cells are stimulated to produce IL-6,²⁶ which promotes the accumulation of Th17 cells. These release IL-17 and IL-22, thereby mediating a barrier-protective response. IL-17 contributes to immune surveillance and oral mucosa integrity, playing a major role in the regulation of epithelial tight junction protein expression, triggering antimicrobial peptide expression, and inducing the release of neutrophil chemoattractants.⁵⁷

B7 Homolog 1 (B7-H1; also known as PD-L1) is abundantly expressed in spinous cells but its expression is not detected in the basement membrane. Furthermore, B7-H1 is not consistently expressed in other oral-lining epithelia or other mucosal sites. As depicted in Fig. 3, B7-H1, expressed on keratinocytes, directly interacts with PD-1 expressed on tissue-resident CD4⁺ T cells that react to exogenous antigens presented through the mucosal surface, thereby protecting against excessive tissue damage and inducing local immune tolerance through the activation of IL-10-secreting T cells.^{58,59}

B7-H1 is not expressed in the lining mucosa under physiological conditions. Following 12-*O*-tetradecanoylphorbol-13-acetate (TPA) painting, basal cell proliferation was observed,






Fig. 2 Timeline. The key anti-inflammatory mechanisms in the oral mucosa are depicted in chronological order.

along with the induction of B7-H1 in the outer layer; however, B7-H1 enrichment was not detected at the junction with the basement membrane.

Biomedical applications of oral mucosa

Oral mucosa grafts

Soft tissue grafts are the gold standard in clinical practice for filling tissue defects and promoting tissue regeneration.⁶⁰ Oral mucosa grafting is widely used in periodontal surgery for increasing keratinized tissue.⁶¹ Free gingival grafts and connective tissue grafts effectively increase the width of keratinized mucosa and decrease *peri*-implant mucosal recession.⁶² A 5-year randomized controlled trial confirmed that free gingival grafts are more effective than collagen matrix in regenerating keratinized mucosa.⁶³ Over the past five years, significant advancements have been made in the biomedical applications of oral mucosa, as summarized in Table 2.

Besides periodontal surgery, oral mucosal grafting techniques are also employed in tissue repair within the respiratory, urinary, and digestive systems, among others.^{64,65} Buccal and lingual mucosae are widely used for urethroplasty.^{66,67} The permanent functional restoration of lengthy abnormal tracheal segments was achieved *via* a reconstructed tracheal replacement strategy that involved cartilage regeneration, microsurgery, and oral mucosa grafting.⁶⁸ An autologous oral mucosa transplant was utilized to create a sophisticated tracheal substitute with excellent epithelialization and minimal granulation, which helped to reduce airway stenosis and early mortality following tracheoplasty while holding promise for conversion to ciliated epithelium.⁶⁷ The utilization of lower labial mucosa effectively addresses focal cicatricial entropion by creating a mucosal membrane that prevents scarring and ensures the mechanical separation of the anterior and posterior lamellae.⁶⁸ A sandwich technique combining ear cartilage and oral

mucosal transplants⁶⁹ with osteochondral flap-plasty is a safe and straightforward surgical treatment for full-thickness eyelid restoration.⁸

Despite their potential, mucosal grafts have some limitations, such as the difficulty in recovering the donor region under pathological inflammatory conditions and the restricted size and functional capacity of the grafts. Consequently, it is necessary to incorporate biomaterial techniques to enhance treatment efficacy and minimize harm to patients.

Stem cell suspensions and secretions

When directly seeded into wounds, stem cells derived from oral mucosa facilitate the healing process. Kuperman *et al.* administered subcutaneous injections of mouse oral mucosa stem cells (mOMSCs), suspended in PBS, around and beneath the skin wounds of diabetic mice, providing proof-of-principle for the potential of stem cell injection therapy.³ Stem cells derived from the oral mucosa can undergo gene editing, thereby enhancing their wound-healing capacity. The seeding of oral keratinocytes and fibroblasts transfected with TGF- β 1 small interfering RNA (siRNA) onto sterile bladder acellular matrix grafts (BAMGs) reduced the formation of urethral scars.⁹⁰

Factors secreted from cells, including cytokines, exosomes, and miRNAs, are utilized in applied biomedical engineering. After comparing the differences in wound healing between oral mucosa and skin, Kong *et al.* embedded exogenous epidermal growth factor (EGF) in layered self-assembled microcapsules and basic fibroblast growth factor (bFGF) in hydrogel to mimic the growth factor release pattern of the oral mucosa.⁹¹ It has been reported that exosomes obtained from gingiva-derived mesenchymal stem cells (GMSC)-can reduce pro-inflammatory factor production in M1 macrophages, highlighting the anti-inflammatory capacity of exosome therapy.⁶⁸ Shi *et al.* loaded exosomes derived from GMSCs into a chitosan/silk hydrogel sponge and observed that this combination enhanced angiogenesis and neuronal ingrowth, thereby facilitating skin repair in diabetic rats.⁹² Exosomes from






Fig. 3 The major anti-inflammatory mechanisms in masticatory and lining mucosa. Specific B7-H1 presentation on masticatory mucosa and *trans*-inhibition by B7-H1-expressing keratinocytes regulate CD4⁺ T-cell-mediated mucosal tissue inflammation. (A) B7-H1 is not detected in stable lining mucosa. Basal cell proliferation and B7-H1 induction in the outer layer were observed after 12-*O*-tetradecanoylphorbol-13-acetate (TPA) painting; however, B7-H1 accumulation was not detected at the basal membrane junction. (B) When the masticatory mucosa is exposed to prolonged external stimuli, such as mastication, epithelial cells secrete IL-6, which promotes the differentiation of T-helper 17 (Th17) cells. These release IL-17 and a small amount of IL-22, thereby mediating a barrier-protective response. B7-H1 is a key signal in spinous cells but not basal cells and is not expressed by other epithelial cells in the lining mucosa. B7-H1 expressed on keratinocytes protects against excessive tissue damage and induces local immunological tolerance by directly interacting with PD-1-expressing tissue-resident CD4⁺ T cells that react with external antigens presented across the mucosal surface. Created in BioRender. Cai, W. (2025) This document is to confirm that <https://BioRender.com/v02r254>.

oral mucosa epithelial cell (OMEC) sheets effectively accelerated wound healing in both allogeneic and autologous scenarios.⁹³ Knight *et al.* demonstrated that small extracellular vesicles (sEVs) secreted by oral mucosa lamina propria-progenitor cells (OMLP-PCs) are superior to commonly used MSC-derived sEVs in facilitating rapid and scarless wound healing.⁶⁹ Skin wound healing can also be accelerated by the overexpression of oral mucosa-specific miRNAs, such as miR-31 and miR-21, that are upregulated during the healing process.^{94,95}

Cell sheets

Oral mucosal cell sheets have exhibited regeneration-promoting effects on skin wound healing and may represent an alternative strategy for tissue regeneration therapy.^{96,97} Cell

sheets maintain the integrity of the extracellular matrix (ECM), thus supporting and guiding cell proliferation and differentiation. Monolayer cultures involve seeding cells onto plastic dishes, collagen membranes, or other biomaterial surfaces, followed by their implantation into tissues to promote the wound-healing effect.⁷¹ Jiang *et al.* fabricated scaffold-free 3D aggregates of hard palate-derived MSCs (PMSCs) using light-controlled cell sheet technology and reported that they promote bone generation.⁷²

Tissue-engineered oral mucosal epithelial cell sheets have a stratified, squamous, non-keratinized shape and cytokeratin expression comparable to that of native esophageal epithelium.⁹⁸ Several studies have established the safety and effectiveness of esophageal regeneration treatment employing autologous oral mucosal epithelial cell sheets, particularly in the



Table 2 Biomedical applications of oral mucosa over the past five years (2020–2025)

Medical application	Disease	Sources	Form	Outcome	Ref.
Oral mucosa grafts	Peri-implant disease	Gingival mucosa	Free Gingival graft (FGG)	Increased keratinized mucosa (KM) width and decreased mucosal recession of <i>peri</i> -implant	62 and 63
	Vesicovaginal fistula (VVF)	Buccal mucosal	Buccal mucosal graft (BMG)	Repair the VVF	64
	Rectovaginal fistula (RVF)	Buccal mucosal	BMG	Repair the RVF	65
	Ureteral strictures	Lingual mucosa	Robotic ureteroplasty with a lingual mucosal graft (RU-LMG)	Medium-term success in managing ureteral strictures	66
	Cicatricial entropion	Buccal mucosal	BMG	Reduction of focal cicatricial entropion	67
Stem cells suspension and secretions	Diabetic wound	Oral mucosa stem cells (mOMSCs)	Subcutaneous injection of cells	Accelerated wound healing, re-epithelialization, and granulation tissue formation	3
	Periodontitis	Gingival mesenchymal stem cell (GMSC)	Exosome	Reduce M1 macrophage and promote transformation of M1 to M2	68
	Skin wound	Oral Mucosa Lamina Propria-Progenitor Cells (OMLP-PCs)	Small extracellular vesicle (sEV)	Minimized scar formation in wound healing	69
	Bone defect	Periodontal ligament stem cell (PDLSC)	sEV	Accelerated repair of bone defect	70
Cell sheets	Periodontitis	PDLSC	Microtissues and monolayers	PDLSC microtissue could be a potential substantial material for guided tissue regeneration (GTR)	71
	<i>Peri</i> -implant disease	Hard palatal-derived mesenchymal stem cells (PMSCs)	Light-controlled scaffold- and serum-free PMSC aggregates	Enhanced bone formation and implant osseointegration	72
	Congenital esophageal atresia	Buccal mucosa	Cell sheet	Effective prevention of endoscopic balloon dilatation and following transplantation	73 and 74
	Oesophageal cancer	Oral mucosa	Cell sheet	Inhibition of pro-inflammatory cytokines	75
	Limbal stem cell deficient	Oral mucosa	Cell sheet carried by amniotic membrane	Transplant for corneal recovery	76
	Periodontitis	PDLSC	Triple-layer cell sheet	Promote osteogenic lineage commitment through improved cell viability and mitochondrial function	77
	Tissue injury	PDLSC	A Janus bio patch engineered by integrating the bioactive patch with a stem cell sheet of PDLSCs	Combine immunomodulatory effects with osteoblastic capacity for enhanced bone regeneration	78
Biomaterial scaffolds	Anterior urethral strictures	Oral mucosa	Tissue-engineered oral mucosa graft MukoCell®	MukoCell® evaluated as a promising alternative for long-segment ureteral reconstruction	79 and 80
	Periodontitis	PDLSC	Electrospinning and collagen hydrogels incorporated PDLSCs and curcumin-loaded ZIF-8 nanoparticles (CURZIF-8)	Regulation of inflammation and promotion of pro-healing factor expression	81
	Periodontitis	Gingival fibroblasts (GF)	GF-laden β -calcium triphosphate	Reduction in vertical pocket depth and bone regeneration	82
	Periodontitis	PDLSC	PDLSC-laden bioinks	Mimic native ECM condition to facilitate PDL regeneration	83 and 84
	Cleft alveolus	GMSC	Predifferentiated GMSCs toward an osteogenic lineage combined with a self-assembling hydrogel scaffold PuraMatrix™ (PM) and bone morphogenetic protein 2 (BMP2)	Enhanced bone regeneration in alveolar clefts	85
	Sensorineural hearing loss	GMSC	GMSC-laden hybrid hydrogel scaffold based on peptide modified alginate and Matrigel with growth factors	Enhance the auditory differentiation potential of GMSCs	86

field of endoscopic transplantation.^{73,74} It was reported that cell sheet transplantation can prevent postoperative strictures by decreasing the levels of pro-inflammatory and anti-tumor cytokines in patients with esophageal cancer.⁷⁵

Oral and corneal epithelia share features such as limited differentiation stages, fast cell renewal, rapid proliferation and expansion, and the absence of a tendency toward keratinization. Nakamura *et al.* cultivated autologous oral epithelial cell



sheets (OMECs) using amniotic membranes as a carrier and found them to be beneficial for the treatment of severe ocular surface disorders following their transplantation.^{7,99,100} The use of OMECs can decrease the probability of postoperative immunological rejection, block corneal neovascularization, accelerate corneal epithelialization, limit the inflammatory response, promote corneal ulcer repair, and improve vision.¹⁷ 3T3 or limbal niche feeder cells can reportedly further improve the effect of OMEC transplantation *via* the secretion of cytokines.^{76,101}

Multi-layered cell sheets have been created for complex tissue regeneration. Fullaondo *et al.* used plasma rich in growth factors (PRGF) fibrin membranes as the carrier for human periodontal ligament stem cell (hPDLSC) culture to generate a triple-layer cell sheet.⁷⁷ Iwata *et al.* built three-layered PDLSC sheets reinforced with woven polyglycolic acid that significantly enhanced periodontal bone regeneration.¹⁰² Meanwhile, Zhou *et al.* isolated adipose-derived stem cells (ADSCs), OMECs, and oral mucosal fibroblasts and combined them to reconstruct full-thickness urethras labeled with ultrasmall super-paramagnetic iron oxide.¹⁰³

Oral mucosal cell sheets possess substantial developmental potential; however, their utilization requires considerable investment in both time and financial resources.

Biomaterial scaffolds

Advancements in biocompatible materials have expanded our capabilities beyond merely supplying engineered cells, now allowing the construction of a microenvironment that is specifically tailored to promote efficient wound healing and tissue regeneration.¹⁰⁴

Engineered tissue can be an optimal biomedical scaffold. The use of decellularized extracellular matrix sheets derived from oral mucosa cells represents a promising approach for the development of novel materials, as their microenvironmental properties are beneficial for wound healing in the oral mucosa.^{105,106} Bhargava *et al.* seeded keratinocytes and fibroblasts derived from oral mucosa on the surface of de-epidermized dermis (DED) for 7 days, obtaining tissue-engineered buccal mucosa for substitution urethroplasty.^{107,108}

The cellularization of a scaffold containing oral mucosa increases vascularization and the establishment of the urothelial barrier, both of which help lower urine leakage-induced local inflammation and fibrosis.¹⁰⁹ Huang *et al.* constructed a three-dimensional porous bacterial cellulose scaffold seeded with lingual keratinocytes that enhanced urethral tissue regeneration.¹¹⁰ MukoCell[®], approved for clinical use in Germany, is a biomedical scaffold mainly consisting of an animal-origin biodegradable scaffold and autologous living OMECs.⁷⁹ The application of MukoCell achieves a similar success rate but with reduced surgery time compared with oral mucosa grafts, indicating that tissue-engineered products can be a feasible alternative for use in tissue reconstruction.⁸⁰

Biomaterial scaffolds can integrate multiple functions, including proliferation, anti-inflammatory effects, sustained release, and conditional dosing, which enables the dynamic

regulation of oral mucosal applications.^{111,112} Lan *et al.* combined a polycaprolactone/collagen/cellulose acetate electrospun scaffold with collagen hydrogels containing PDLSCs and curcumin-loaded ZIF-8 nanoparticles, a strategy that enhanced anti-inflammatory and antioxidative capacity.⁸¹ Novel pore-forming bioink technology allows for the zonal positioning of stem cells and plasmids encoding genes of interest.¹¹³ Collagen-based bioink containing PDLSCs facilitated periodontal ligament regeneration and enhanced interfacial integration.⁸³

The integration of biomaterial scaffolds with oral mucosa-derived stem cells can significantly influence the direction of cellular differentiation. Kandam *et al.* combined PuraMatrix (a self-assembling hydrogel scaffold), bone morphogenetic protein 2 (BMP2), and GMSCs pre-differentiated toward an osteogenic lineage and found that this biomaterial scaffold achieved superior bone-regenerating capacity in athymic nude rats compared to the use of transplant material or cells alone.⁸⁵ It has been reported that oral mucosa-derived stem cells, encapsulated in an optimized three-dimensional scaffold alongside growth factors, display auditory differentiation potential.⁸⁶ Three-dimensional printing allows for the precise control of biomaterial scaffolds and cells, thereby enabling the arrangement of complex structures within defect regions.¹¹⁴ Using multi-phasic scaffolds, proliferation and differentiation across positions and over time can be controlled, thereby facilitating the regeneration of both soft and osseous tissue in the periodontium.¹¹⁵ For example, Lee *et al.* manufactured a region-specific, tri-phasic microstructure for generating mineralized tissue, fiber alignment, and bone tissue.¹¹⁶ The multifunctionality of biomaterial scaffolds renders oral mucosa cells an intriguing option for disease treatment.

Advantages of oral mucosa-derived biomaterials

Diverse sources of acquisition

As illustrated in Fig. 4, ease of access is a substantial benefit in the biomaterial application of cells sourced from oral mucosa. All oral mucosa-derived cells can be disposed of enzymatically and cultured *in vitro*. The oral mucosa, especially the gingival tissue covering the alveolar bone and the third molar area, is frequently incised during dental procedures such as tooth extraction and gingivoplasty. This makes the procurement of oral mucosa relatively straightforward and minimizes ethical concerns.

Oral mucosa is an abundant source of both adult and pluripotent stem cells. Compared with stem cells derived from other tissues, those derived from oral mucosa exhibit significantly higher growth rates and regeneration potential.^{117,118} Commonly used adult stem cells include PDLSCs, oral epithelial progenitor/stem cells (OESCs), and GMSCs.¹¹⁹ MSC-like cells derived from oral mucosa, such as gingival fibroblasts and periodontal ligament fibroblasts, can be effectively reprogrammed into pluripotent stem cells, exhibiting multipotentiality following transduction with a retroviral cocktail. Moreover,



Application of Oral mucosa




Fig. 4 Biomedical applications of oral mucosa and advantages of oral mucosa-derived biomaterials. Overview of biomedical applications of oral mucosa, including oral mucosa grafts, stem cell suspensions and secretions, cell sheets, and biomaterial scaffolds. Key advantages of oral mucosa-derived biomaterials are also presented, such as diverse sources of acquisition, immunomodulation, and scarless healing, demonstrating its versatility and potential in regenerative medicine and clinical applications. Created in BioRender. Cai, W. (2025) <https://BioRender.com/c17a564>.

the reprogramming efficacy of oral fibroblasts surpasses that of skin fibroblasts.¹²⁰ The accessibility and the potential for modification of oral mucosa-derived cells are fundamental to their application as biomaterials.

Immunomodulation

The wound healing rate of the oral mucosa is significantly greater than that of skin, which can be attributed to the diminished inflammatory response in the former.^{121,122} Studies have shown that PDLSCs and gingival fibroblasts possess the immunomodulatory properties of lymphocytes.^{123,124} Recent studies have demonstrated that PITX1, a transcription factor that maintains the unique balance of immune cells, is highly expressed in oral epithelial tissues, whereas its expression is undetectable in cutaneous keratinocytes.^{125,126} In addition, oral mucosa contains abundant stem cells and fibroblasts. Fibroblasts are the predominant cell type, which exhibited MSC-like properties and low immunogenicity.^{127–129} It has also been suggested that MSCs derived from oral mucosa hold potential as tools for use in

biomaterial-based immunotherapy.¹³⁰ Moreover, PDLSC spheroids show increased anti-inflammatory and angiogenic capabilities, possibly due to changes in apoptosis-related signaling.¹³¹

Scarless healing

The main factors responsible for the scarless healing of oral mucosal wounds include the specific pattern of inflammatory regulation, a high proliferation rate, and efficient ECM remodeling. The expression level and influence of fibromodulin are crucial for scarless repair. During skin wound healing, periostin is highly expressed in fibrotic scars. However, during oral mucosal wound healing, its expression is lower than that in skin, which helps prevent fibrosis.¹³² In wound healing experiments involving rats, an inverse correlation is observed between fibromodulin expression and scar formation, with adult rats exhibiting reduced fibromodulin levels and enhanced scar formation compared to fetal rats.¹³³

The scarless healing property of the oral mucosa renders it an ideal source for biomaterials in tissue regeneration. The buccal



mucosa in urethraloplasty in rabbits exhibits marked scarless healing outcomes, characterized by extensive neovascularization, minimal inflammatory cell infiltration, and minimal fibrosis.¹³⁴

Challenges and future directions

Compared to skin, oral mucosa exhibits superior immune regulation in response to damage owing to its prolonged exposure to mastication stimulation and microbiome symbiosis. Differential modulation of inflammation and immune responses may also assist in site-specific healing. It is unclear if differences between the oral and skin microbiomes influence the healing of oral mucosal wounds because Th17 cells in the gums function independently of symbiotic colonization pathways.

The intensity and duration of the inflammatory response play a significant role during wound healing. The substantial antibacterial defenses and anti-inflammatory capabilities of the oral mucosa slow the inflammatory response, encouraging faster healing with minimal scarring. Keratinocytes and stromal cells are involved in this process. Recent research has demonstrated that B7-H1, which is expressed on keratinocytes

in the masticatory mucosa, directly interacts with tissue-resident CD4⁺ T cells that express PD-1, thereby supporting mucosal healing and preventing excessive inflammation. Unlike previous studies that focused on specific regions of the oral mucosa, this study distinguished between the masticatory mucosa and the lining mucosa, offering a better comparison of the mechanisms involved in their control of the inflammatory process.

The oral mucosa is an essential raw material for tissue engineering and regenerative medicine applications. Its main characteristics include ease of access, rapid healing, mild inflammation, strong antibacterial ability, and limited immune rejection. OMECs have been extensively used in a variety of regenerative medicine applications, including eye tissue, tracheal, and esophageal therapies.

In summary, a rapid immune response, primarily regulated by changes in gene expression, is essential for the superior wound-healing capacity of the oral mucosa. While most recent studies have focused on cytokines and genes, the specific mechanisms underpinning the regulation of inflammation and the barrier-protective properties of the oral mucosa remain underexplored. A deeper understanding of the mechanisms involved in the regulation of inflammation in the oral mucosa,

Challenges and Future Directions in Oral Mucosa Research




Fig. 5 Challenges and future directions in oral mucosa research and applications. The current challenges and future research directions in the field of oral mucosa-based therapies include elucidating the molecular and cellular mechanisms underlying the unique healing properties of the oral mucosa, developing scalable and standardized production methods, addressing clinical translation challenges, and fostering interdisciplinary collaboration between the fields of medicine, materials science, and chemistry. Created in BioRender. Cai, W. (2025) <https://BioRender.com/a72v147>.



including the influence of the oral microbiota and variations in mucosal structures, will likely enhance the safety, efficacy, and application potential of oral mucosa in tissue regeneration. As outlined in Fig. 5, current challenges and future directions in oral mucosa research include elucidating the molecular and cellular mechanisms underlying its unique healing properties, developing scalable production methods, addressing clinical translation challenges, and fostering interdisciplinary collaboration. Addressing these challenges will be critical for advancing the field of oral mucosa-based therapies.

Conclusions

The oral mucosa exhibits excellent potential for inflammatory and immune regulation during wound healing, thus accelerating recovery and restricting scarring. Additionally, its use as a regenerative material offers several advantages, including an adequate supply, rapid donor site healing, and the absence of mucosal metaplasia after transplantation, presenting excellent regenerative potential. This approach not only furnishes materials for the repair of soft tissue defects but also minimizes the formation of scars, which holds significant clinical value. Future studies should concentrate on key targets and signaling pathways involved in the oral mucosa healing process, alongside preclinical research to support ideal wound healing in the clinic. We anticipate that oral mucosa-based approaches and bionic materials will achieve superior safety and efficacy in the near future, giving patients renewed hope.

Author contributions

Yani Chen: writing – original draft. Bicong Gao: writing – review and editing. Junjin Cai: conceptualization, writing – review and editing. Junhong Lai: writing – review and editing, investigation. Kaichen Lai: writing – review and editing, funding acquisition. Ying Wang: writing – review and editing, project administration.

Data availability

No primary research results, software or code have been included and no new data were generated or analysed as part of this review.

Conflicts of interest

The authors declare that there no conflicts of interest.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 82370928, 82401157).

Notes and references

- O. A. Peña and P. Martin, *Nat. Rev. Mol. Cell Biol.*, 2024, **25**, 599–616.
- A. L. Sánchez, H. A. García-Perdomo and J. A. Robayo, *Nat. Rev. Urol.*, 2023, **20**, 259–260.
- S. Kuperman, R. Efraty, I. Arie, A. Rahmanov, M. Rahmanov Gavrielov, M. Noff, R. Fishel and S. Pitaru, *Int. J. Environ. Res. Public Health*, 2020, **17**, 4854.
- K. L. Yang, S. B. Fan, J. Wang, L. Yin, Z. H. Li, S. W. Xiong, G. P. Han, C. Meng, P. Zhang, X. S. Li and L. Q. Zhou, *Eur. Urol.*, 2022, **81**, 533–540.
- A. L. Sánchez, H. A. García-Perdomo and J. A. Robayo, *Nat. Rev. Urol.*, 2023, **20**, 259–260.
- C. Q. Liang, J. L. Wang, B. Hai, Y. J. Xu, J. M. Zeng, S. S. Chai, J. W. Chen, H. Zhang, X. C. Gao, G. Cheng, X. Yang, T. Hou, W. C. Li, X. Y. Xiao and B. Li, *Eur. Urol.*, 2022, **82**, 193–200.
- S. Komai, T. Inatomi, T. Nakamura, M. Ueta, G. Horiguchi, S. Teramukai, Y. Kimura, T. Kagimura, M. Fukushima, S. Kinoshita and C. Sotozono, *Br. J. Ophthalmol.*, 2022, **106**, 1355–1362.
- M. J. Jin and Y. Gao, *J. Craniofac. Surg.*, 2021, **32**, E660–E661.
- P. Ngowiyutagon, P. Prabhasawat, C. Chirapapaisan, P. Jaru-ampornpan, K. Pornpanich, P. Ekpo, N. Sukon and S. Matamnan, *Cornea*, 2021, **40**, 1482–1486.
- A. Rahal, D. Meller, A. Manthey, R. Pfoertner, S. Lang, N. Bechrakis and H. Westekemper, *Can. J. Ophthalmol.*, 2023, **58**, 543–549.
- D. H.-K. Ma, Y.-J. Hsueh, K. S.-K. Ma, Y.-J. Tsai, S.-F. Huang, H.-C. Chen, C.-C. Sun, M.-T. Kuo, A.-S. Chao and J.-Y. Lai, *Stem Cell Res. Ther.*, 2021, **12**, 524.
- K. E. Zhurenkov, E. I. Alexander-Sinkler, I. O. Gavril'yik, N. M. Yartseva, S. A. Aleksandrova, T. V. Mashel, J. I. Khorolskaya, M. I. Blinova, A. N. Kulikov, S. V. Churashov, V. F. Chernysh and N. A. Mikhailova, *Invest. Ophthalmol. Visual Sci.*, 2022, **63**, 16.
- H. Tshida, T. Kasahara, M. Kiriya, Y. Iwasaki, J. Sugita, K. Ichikawa, T. Ohta and K. Miyahara, *Int. J. Mol. Sci.*, 2023, **24**, 8926.
- S. Lopez, L. Hoz, E. P. Tenorio, B. Buentello, F. S. Magana, A. Wintergerst, A. Navas, Y. Garfias and H. Arzate, *Int. J. Mol. Sci.*, 2021, **22**, 5976.
- A. Simoes, L. Chen, Z. J. Chen, Y. Zhao, S. Gao, P. T. Marucha, Y. Dai, L. A. DiPietro and X. F. Zhou, *Sci. Rep.*, 2019, **9**, 7160.
- Y. Wang and D. N. Tatakis, *J. Periodontol.*, 2021, **92**, 863–874.
- A. I. Toma, J. M. Fuller, N. J. Willett and S. L. Goudy, *Transl. Res.*, 2021, **236**, 17–34.
- A. M. Overmiller, A. P. Sawaya, E. D. Hope and M. I. Morasso, *Cold Spring Harbor Perspect. Biol.*, 2022, **14**, a041244.
- R. Iglesias-Bartolome, A. Uchiyama, A. A. Molinolo, L. Abusleme, S. R. Brooks, J. L. Callejas-Valera, D. Edwards, C. Doci, M. L. Asselin-Labat, M. W. Onaitis,



- N. M. Moutsopoulos, J. S. Gutkind and M. I. Morasso, *Sci. Transl. Med.*, 2018, **10**, eaap8798.
- 20 M. E. Schrementi, A. M. Ferreira, C. Zender and L. A. DiPietro, *Wound Repair Regen.*, 2008, **16**, 80–86.
 - 21 L. Chen, Z. H. Arbieve, S. Guo, P. T. Marucha, T. A. Mustoe and L. A. DiPietro, *BMC Genomics*, 2010, **11**, 471.
 - 22 L. Abusleme, A. K. Dupuy, N. Dutzan, N. Silva, J. A. Burleson, L. D. Strausbaugh, J. Gamonal and P. I. Diaz, *ISME J.*, 2013, **7**, 1016–1025.
 - 23 H. Zhou, S. Gao, X. Duan, S. Liang, D. A. Scott, R. J. Lamont and H. Wang, *FASEB J.*, 2015, **29**, 3737–3749.
 - 24 E. Vescarelli, A. Pilloni, F. Dominici, P. Pontecorvi, A. Angeloni, A. Polimeni, S. Ceccarelli and C. Marchese, *J. Clin. Periodontol.*, 2017, **44**, 1039–1050.
 - 25 S. Kang, C. Zhang, T. Ohno and M. Azuma, *Mucosal Immunol.*, 2017, **10**, 650–660.
 - 26 N. Dutzan, L. Abusleme, H. Bridgeman, T. Greenwell-Wild, T. Zangerle-Murray, M. E. Fife, N. Bouladoux, H. Linley, L. Brenchley, K. Wemyss, G. Calderon, B.-Y. Hong, T. J. Break, D. M. E. Bowdish, M. S. Lionakis, S. A. Jones, G. Trinchieri, P. I. Diaz, Y. Belkaid, J. E. Konkel and N. M. Moutsopoulos, *Immunity*, 2017, **46**, 133–147.
 - 27 J. Y. Park, H. Chung, D. T. DiPalma, X. Tai and J. H. Park, *Mucosal Immunol.*, 2018, **11**, 1092–1102.
 - 28 C. R. Neves, J. Buskermolen, S. Roffel, T. Waaijman, M. Thon, E. Veerman and S. Gibbs, *J. Tissue Eng. Regen. Med.*, 2019, **13**, 1079–1092.
 - 29 L. Chen, Z. Chen, A. Simões, X. Wu, Y. Dai, L. A. DiPietro and X. Zhou, *Int. J. Mol. Sci.*, 2020, **21**, 521.
 - 30 T. R. Leonardo, J. Shi, D. Chen, H. M. Trivedi and L. Chen, *Int. J. Mol. Sci.*, 2020, **21**, 2966.
 - 31 D. W. Williams, T. Greenwell-Wild, L. Brenchley, N. Dutzan, A. Overmiller, A. P. Sawaya, S. Webb, D. Martin, G. Hajishengallis, K. Divaris, M. Morasso, M. Haniffa and N. M. Moutsopoulos, *Cell*, 2021, **184**, 4090–4104.
 - 32 X. Han, J. Ren, H. Lohner, L. Yakoumatos, R. Liang and H. Wang, *J. Biol. Chem.*, 2022, **298**, 102036.
 - 33 J. L. Sanchez-Trincado, H. F. Pelaez-Prestel, E. M. Lafuente and P. A. Reche, *Front. Immunol.*, 2022, **12**, 740613.
 - 34 N. Xue, Y. Wang, H. Cheng, H. Liang, X. Fan, F. Zuo, X. Zeng, N. Ji and Q. Chen, *Front. Immunol.*, 2022, **13**, 1009742.
 - 35 Z. Meng, Z. Li, S. Guo, D. Wu, R. Wei, J. Liu, L. Hu and L. Sui, *Int. J. Mol. Sci.*, 2022, **23**, 13414.
 - 36 X. Xuanyuan, L. Zhang, Y. Zheng, R. Jiang, Y. Ma, R. Liu, P. Hou, M. Lei, H. Xu and H. Zeng, *Commun. Biol.*, 2024, **7**, 1155.
 - 37 F. R. Kirchner and S. LeibundGut-Landmann, *Mucosal Immunol.*, 2021, **14**, 455–467.
 - 38 S. L. Gaffen and N. M. Moutsopoulos, *Sci. Immunol.*, 2020, **5**, eaau4594.
 - 39 F. Momen-Heravi, R. A. Friedman, S. Albeshri, A. Sawle, M. Keschull, A. Kuhn and P. N. Papapanou, *J. Dent. Res.*, 2021, **100**, 549–556.
 - 40 N. M. Moutsopoulos and J. E. Konkel, *Trends Immunol.*, 2018, **39**, 276–287.
 - 41 A. J. Caetano, V. Yianni, A. Volponi, V. Booth, E. M. D'Agostino and P. Sharpe, *eLife*, 2021, **10**, e62810.
 - 42 J. Ren, X. Han, H. Lohner, R. Liang, S. Liang and H. Wang, *J. Immunol.*, 2021, **207**, 268–280.
 - 43 K. M. Fawzy El-Sayed, A. Bittner, K. Schlicht, M. Mekhemar, K. Enthammer, M. Hoepfner, M. Es-Souni, J. Schulz, M. Laudes, C. Graetz, C. E. Doerfer and D. M. Schulte, *Cells*, 2021, **10**, 3310.
 - 44 Y. Huang, L. Zhang, L. Tan, C. Zhang, X. Li, P. Wang, L. Gao and C. Zhao, *Inflammation*, 2023, **46**, 1871–1886.
 - 45 T. R. Leonardo, L. Chen, M. E. Schrementi, J. Shi, P. T. Marucha, K. Glass and L. A. DiPietro, *Wound Repair Regen.*, 2023, **31**, 156–170.
 - 46 W. Zhou, A. S. Pal, A. Y.-H. Hsu, T. Gurol, X. Zhu, S. E. Wirbisky-Hershberger, J. L. Freeman, A. L. Kasinski and Q. Deng, *Cell Rep.*, 2018, **22**, 1810–1823.
 - 47 P. Lopez-Cuevas, C. Xu, C. E. Severn, T. C. L. Oates, S. J. Cross, A. M. Toye, S. Mann and P. Martin, *Adv. Sci.*, 2022, **9**, e2202717.
 - 48 A. D. J. Bombin, N. Dunne and H. O. McCarthy, *Acta Biomater.*, 2023, **155**, 304–322.
 - 49 M. Faas, N. Ipseiz, J. Ackermann, S. Culemann, A. Grueneboom, F. Schroeder, T. Rothe, C. Scholtyssek, M. Eberhardt, M. Boettcher, P. Kirchner, C. Stoll, A. Ekici, M. Fuchs, M. Kunz, B. Weigmann, S. Wirtz, R. Lang, J. Hofmann, J. Vera, D. Voehringer, A. Michelucci, D. Mougiakakos, S. Uderhardt, G. Schett and G. Kroenke, *Immunity*, 2021, **54**, 2531–2546.
 - 50 B. Cheng, A. Rong, Q. Zhou and W. Li, *J. Exp. Clin. Cancer Res.*, 2020, **39**, 5.
 - 51 L. Chen, Z. Chen, A. Simoes, X. Wu, Y. Dai, L. A. DiPietro and X. Zhou, *Int. J. Mol. Sci.*, 2020, **21**, 521.
 - 52 Y. W. Iwasaki, M. C. Siomi and H. Siomi, in *Annual Review of Biochemistry*, ed. R. D. Kornberg, 2015, vol. 84, pp. 405–433.
 - 53 M. A. Rojas, S. Ceccarelli, G. Gerini, E. Vescarelli, L. Marini, C. Marchese and A. Pilloni, *J. Clin. Periodontol.*, 2021, **48**, 705–720.
 - 54 M. Rodrigues, N. Kosaric, C. A. Bonham and G. C. Gurtner, *Physiol. Rev.*, 2019, **99**, 665–706.
 - 55 M. Lodyga and B. Hinz, *Semin. Cell Dev. Biol.*, 2020, **101**, 123–139.
 - 56 J. M. Moreau, M. Velegraki, C. Bolyard, M. D. Rosenblum and Z. Li, *Sci. Immunol.*, 2022, **7**, eabi4613.
 - 57 L. Abusleme and N. M. Moutsopoulos, *Oral Dis.*, 2017, **23**, 854–865.
 - 58 S. Kang, C. Zhang, T. Ohno and M. Azuma, *Mucosal Immunol.*, 2017, **10**, 650–660.
 - 59 X. Zhou, Y. Zhou, Q. Ding, Z. Jiao, L. Lu, N. Yang, Y. Ma and K.-Y. Chou, *Transplant Immunol.*, 2009, **21**, 192–197.
 - 60 L. Chambrone, J. Botelho, V. Machado, P. Mascarenhas, J. J. Mendes and G. Avila-Ortiz, *J. Periodontol.*, 2022, **93**, 1336–1352.
 - 61 E. T. Scheyer, M. Sanz, S. Dibart, H. Greenwell, V. John, D. M. Kim, L. Langer, R. Neiva and G. Rasperini, *J. Periodontol.*, 2015, **86**, S73–S76.



- 62 S. L. Oh, S. Shahami, L. J. Bernal-Cepeda, Y. Fu and M. K. Chung, *J. Prosthodont. Res.*, 2025, **69**, 4–11.
- 63 D. Wei, Q. Wang, H. Sui, Y. Qin, H. Zhang, H. Meng and J. Han, *Clin. Implant. Dent. Relat. Res.*, 2025, **27**, e13422.
- 64 K. M. Taha, M. I. Mohamed, E. Desoky, M. M. Seleem and A. M. Fawzi, *Neurourol. Urodyn.*, 2025, **44**, 287–293.
- 65 C. Cahill, N. Kruger and J. Heine, *JMIR Res. Protoc.*, 2022, **11**, e31003.
- 66 K. Yang, S. Fan, J. Wang, L. Yin, Z. Li, S. Xiong, G. Han, C. Meng, P. Zhang, X. Li and L. Zhou, *Eur. Urol.*, 2022, **81**, 533–540.
- 67 P. S. Saffari, K. A. Roelofs and D. B. Rootman, *Indian J. Ophthalmol.*, 2025, **73**, 305–306.
- 68 R. Wang, Q. Ji, C. Meng, H. Liu, C. Fan, S. Lipkind, Z. Wang and Q. Xu, *Int. Immunopharmacol.*, 2020, **81**, 106030.
- 69 R. Knight, E. Board-Davies, H. Brown, A. Clayton, T. Davis, B. Karatas, J. Burston, Z. Tabi, J. M. Falcon-Perez, S. Paisey and P. Stephens, *Stem Cells Transl. Med.*, 2022, **11**, 861–875.
- 70 B. Zhao, Q. Chen, L. Zhao, J. Mao, W. Huang, X. Han and Y. Liu, *Int. J. Nanomed.*, 2022, **17**, 519–536.
- 71 K. Janjić, H. Agis, A. Moritz, X. Rausch-Fan and O. Andrukhov, *J. Periodontol.*, 2022, **93**, 697–708.
- 72 Z. Jiang, N. Li, Q. Shao, D. Zhu, Y. Feng, Y. Wang, M. Yu, L. Ren, Q. Chen and G. Yang, *Bioeng. Transl. Med.*, 2023, **8**, e10334.
- 73 A. Fujino, Y. Fuchimoto, T. Mori, M. Kano, Y. Yamada, M. Ohno, Y. Baba, N. Isogawa, K. Arai, T. Yoshioka, M. Abe, N. Kanai, R. Takagi, M. Maeda and A. Umezawa, *Stem Cell Res. Ther.*, 2023, **14**, 86.
- 74 A. Fujino, Y. Fuchimoto, Y. Baba, N. Isogawa, T. Iwata, K. Arai, M. Abe, N. Kanai, R. Takagi, M. Maeda and A. Umezawa, *Stem Cell Res. Ther.*, 2022, **13**, 35.
- 75 A. Yoshida, T. Takata, T. Kanda, N. Yamaguchi, H. Minami, K. Nakao, S. Kobayashi, S. Eguchi and H. Isomoto, *Sci. Rep.*, 2021, **11**, 15282.
- 76 J. Oliva, F. Bardag-Gorce and Y. Niihara, *Int. J. Mol. Sci.*, 2020, **21**, 411.
- 77 A. Fullaondo, M. Zalduendo, N. Osinalde, M. H. Alkhraisat, E. Anitua and A. M. Zubiaga, *Regener. Med.*, 2025, 1–14, DOI: [10.1080/17460751.2024.2445931](https://doi.org/10.1080/17460751.2024.2445931).
- 78 S. Liu, W. Wang, Z. Chen, P. Wu, W. Pu, G. Li, J. Song and J. Zhang, *Adv. Sci.*, 2024, **11**, e2401882.
- 79 L. Karapanos, I. Akbarov, V. Zugor, R. Kokx, A. Hagemeyer and A. Heidenreich, *Int. J. Urol.*, 2021, **28**, 936–942.
- 80 L. Karapanos, V. Knorr, L. Halbe, M. Schmautz, B. Ergashev and A. Heidenreich, *Int. J. Urol.*, 2023, **30**, 1000–1007.
- 81 X. Lan, Y. Wang and M. Yin, *Int. J. Nanomed.*, 2025, **20**, 887–906.
- 82 M. Abdal-Wahab, K. A. Abdel Ghaffar, O. M. Ezzatt, A. A. Hassan, M. M. S. El Ansary and A. Y. Gamal, *J. Periodontal Res.*, 2020, **55**, 441–452.
- 83 I. J. de Souza Araújo, R. S. Perkins, M. M. Ibrahim, G. T. Huang and W. Zhang, *ACS Appl. Mater. Interfaces*, 2024, **16**, 59979–59990.
- 84 G. T. Yu, W. X. Zhu, Y. Y. Zhao, H. Cui, H. Chen, Y. Chen, T. T. Ning, M. D. Rong, L. Rao and D. D. Ma, *Biofabrication*, 2024, **16**, 025007.
- 85 U. Kandalam, T. Kawai, G. Ravindran, R. Brockman, J. Romero, M. Munro, J. Ortiz, A. Heidari, R. Thomas, S. Kuriakose, C. Naglieri, S. Ejtemai and S. I. Kaltman, *Tissue Eng., Part A*, 2021, **27**, 424–436.
- 86 S. Pouraghaei, F. Mozarzadeh, C. Chen, S. Ansari and A. Moshaverinia, *ACS Biomater. Sci. Eng.*, 2020, **6**, 2263–2273.
- 87 G. Tsachouridis, R. Nijman, L. M. O. de Kort and P. de Graaf, *Pediatr. Surg. Int.*, 2025, **41**, 79.
- 88 J. Ren, Y. Xu, Z. Guo, R. Ting, J. Ren, W. Kan, Y. Luo, M. Zhu and T. Qiang, *Thorac. Cancer*, 2022, **13**, 284–295.
- 89 N. Yamamoto, H. Ogi, S. Yanagibayashi, R. Yoshida, M. Takikawa, A. Nishijima and T. Kiyosawa, *Plast. Reconstr. Surg. Glob Open*, 2017, **5**, e1301.
- 90 C. Li, Y.-M. Xu, Z.-S. Liu and H.-B. Li, *Urology*, 2013, **81**, 1075–1080.
- 91 X. Kong, J. Fu, K. Shao, L. Wang, X. Lan and J. Shi, *Acta Biomater.*, 2019, **100**, 255–269.
- 92 Q. Shi, Z. Qian, D. Liu, J. Sun, X. Wang, H. Liu, J. Xu and X. Guo, *Front. Physiol.*, 2017, **8**, 904.
- 93 S. Sjoqvist, T. Ishikawa, D. Shimura, Y. Kasai, A. Imafuku, S. Bou-Ghannam, T. Iwata and N. Kanai, *J. Extracell. Vesicles*, 2019, **8**, 1565264.
- 94 L. Chen, A. Simoes, Z. Chen, Y. Zhao, X. Wu, Y. Dai, L. A. DiPietro and X. Zhou, *Int. J. Mol. Sci.*, 2019, **20**, 3679.
- 95 J. Shi, X. Ma, Y. Su, Y. Song, Y. Tian, S. Yuan, X. Zhang, D. Yang, H. Zhang, J. Shuai, W. Cui, F. Ren, M. V. Plikus, Y. Chen, J. Luo and Z. Yu, *J. Invest. Dermatol.*, 2018, **138**, 2253–2263.
- 96 J. Lee, D. Shin and J.-L. Roh, *Head Neck*, 2019, **41**, 774–779.
- 97 J.-L. Roh, J. Lee, E. H. Kim and D. Shin, *Oral Oncol.*, 2017, **75**, 81–88.
- 98 N. Yamaguchi, H. Isomoto, S. Kobayashi, N. Kanai, K. Kanetaka, Y. Sakai, Y. Kasai, R. Takagi, T. Ohki, H. Fukuda, T. Kanda, K. Nagai, I. Asahina, K. Nakao, M. Yamato, T. Okano and S. Eguchi, *Sci. Rep.*, 2017, **7**, 17460.
- 99 T. Nakamura, T. Inatomi, C. Sotozono, T. Amemiya, N. Kanamura and S. Kinoshita, *Br. J. Ophthalmol.*, 2004, **88**, 1280–1284.
- 100 C. Sotozono, T. Inatomi, T. Nakamura, N. Koizumi, N. Yokoi, M. Ueta, K. Matsuyama, H. Kaneda, M. Fukushima and S. Kinoshita, *Acta Ophthalmol.*, 2014, **92**, e447–e453.
- 101 C.-Y. Duan, H.-T. Xie, X.-Y. Zhao and M.-C. Zhang, *Regener. Med.*, 2019, **14**, 49–62.
- 102 T. Iwata, M. Yamato, H. Tsuchioka, R. Takagi, S. Mukobata, K. Washio, T. Okano and I. Ishikawa, *Biomaterials*, 2009, **30**, 2716–2723.
- 103 S. Zhou, R. Yang, Q. Zou, K. Zhang, T. Yin, W. Zhao, J. G. Shapter, G. Gao and Q. Fu, *Theranostics*, 2017, **7**, 2509–2523.
- 104 T. Wu, X. Li, J. Xue and Y. Xia, *Acc. Mater. Res.*, 2024, **5**, 1507–1519.
- 105 C. Liu, M. Pei, Q. Li and Y. Zhang, *Front. Med.*, 2022, **16**, 56–82.



- 106 L. Ren, Z. Jiang, H. Zhang, Y. Chen, D. Zhu, J. He, Y. Chen, Y. Wang and G. Yang, *Mater. Today Bio*, 2023, **22**, 100734.
- 107 S. Bhargava, J. M. Patterson, R. D. Inman, S. MacNeil and C. R. Chapple, *Eur. Urol.*, 2008, **53**, 1263–1269.
- 108 Z. Xuan, V. Zachar and C. P. Pennisi, *Int. J. Mol. Sci.*, 2022, **23**, 14074.
- 109 N. I. Osman, J. M. Patterson, S. MacNeil and C. R. Chapple, *Eur. Urol.*, 2014, **66**, 790–791.
- 110 J. W. Huang, X. G. Lv, Z. Li, L. J. Song, C. Feng, M. K. Xie, C. Li, H. B. Li, J. H. Wang, W. D. Zhu, S. Y. Chen, H. P. Wang and Y. M. Xu, *Biomed. Mater.*, 2015, **10**, 055005.
- 111 S. D. Dutta, J. Hexiu, M. Moniruzzaman, T. V. Patil, R. Acharya, J. S. Kim and K. T. Lim, *Biomaterials*, 2025, **316**, 122991.
- 112 S. Shahrudi, A. Parvinnasab, E. Salahinejad, S. Abdi, S. Rajabi and L. Tayebi, *Carbohydr. Polym.*, 2025, **349**, 123036.
- 113 T. Gonzalez-Fernandez, S. Rathan, C. Hobbs, P. Pitacco, F. E. Freeman, G. M. Cuniffe, N. J. Dunne, H. O. McCarthy, V. Nicolosi, F. J. O'Brien and D. J. Kelly, *J. Controlled Release*, 2019, **301**, 13–27.
- 114 I. Roato, B. Masante, G. Putame, D. Massai and F. Mussano, *Nanomaterials*, 2022, **12**, 3878.
- 115 S. Ivanovski, C. Vaquette, S. Gronthos, D. W. Huttmacher and P. M. Bartold, *J. Dent. Res.*, 2014, **93**, 1212–1221.
- 116 C. H. Lee, J. Hajibandeh, T. Suzuki, A. Fan, P. Shang and J. J. Mao, *Tissue Eng., Part A*, 2014, **20**, 1342–1351.
- 117 M. E. Cabaña-Muñoz, M. J. Pelaz Fernández, J. M. Parmigiani-Cabaña, J. M. Parmigiani-Izquierdo and J. J. Merino, *Pharmaceutics*, 2023, **15**, 2109.
- 118 G. B. Tomar, R. K. Srivastava, N. Gupta, A. P. Barhanpurkar, S. T. Pote, H. M. Jhaveri, G. C. Mishra and M. R. Wani, *Biochem. Biophys. Res. Commun.*, 2010, **393**, 377–383.
- 119 H. Egusa, W. Sonoyama, M. Nishimura, I. Atsuta and K. Akiyama, *J. Prosthodont. Res.*, 2012, **56**, 151–165.
- 120 N. Wada, B. Wang, N. H. Lin, A. L. Laslett, S. Gronthos and P. M. Bartold, *J. Periodontal Res.*, 2011, **46**, 438–447.
- 121 A. M. Szpaderska, J. D. Zuckerman and L. A. DiPietro, *J. Dent. Res.*, 2003, **82**, 621–626.
- 122 H. Yuan, G. E. Chlipala, H. I. Bangash, R. Meenakshi, D. Chen, H. M. Trivedi, L. A. DiPietro, P. Gajendrareddy and L. Chen, *J. Dent. Res.*, 2025, **104**, 97–105.
- 123 N. Wada, D. Menicanin, S. Shi, P. M. Bartold and S. Gronthos, *J. Cell. Physiol.*, 2009, **219**, 667–676.
- 124 A. R. Sanz, F. S. Carrión and A. P. Chaparro, *Periodontology* 2000, 2015, **67**, 251–267.
- 125 A. M. Overmiller, A. Uchiyama, E. D. Hope, S. Nayak, C. G. O'Neill, K. Hasneen, Y. W. Chen, F. Naz, S. Dell'Orso, S. R. Brooks, K. Jiang and M. I. Morasso, *JCI Insight*, 2024, **9**, e182844.
- 126 R. Iglesias-Bartolome, A. Uchiyama, A. A. Molinolo, L. Abusleme, S. R. Brooks, J. L. Callejas-Valera, D. Edwards, C. Doci, M. L. Asselin-Labat, M. W. Onaitis, N. M. Moutsopoulos, J. S. Gutkind and M. I. Morasso, *Sci. Transl. Med.*, 2018, **10**, eaap8798.
- 127 K. Marynka-Kalmani, S. Treves, M. Yafee, H. Rachima, Y. Gafni, M. A. Cohen and S. Pitaru, *Stem Cells*, 2010, **28**, 984–995.
- 128 S. Diar-Bakirly and T. El-Bialy, *Saudi J. Biol. Sci.*, 2021, **28**, 2518–2526.
- 129 A. Fadl and A. Leask, *Cells*, 2023, **12**, 2021.
- 130 O. Andrukhov, A. Blufstein and C. Behm, *Front. Oral. Health*, 2021, **2**, 832976.
- 131 K. Iwasaki, M. Nagata, K. Akazawa, T. Watabe and I. Morita, *J. Periodontal Res.*, 2019, **54**, 364–373.
- 132 G. Nikoloudaki, K. Creber and D. W. Hamilton, *Am. J. Physiol.: Cell Physiol.*, 2020, **318**, C1065–C1077.
- 133 C. Soo, F. Y. Hu, X. Zhang, Y. Wang, S. R. Beanes, H. P. Lorenz, M. H. Hedrick, R. J. Mackool, A. Plaas, S. J. Kim, M. T. Longaker, E. Freymiller and K. Ting, *Am. J. Pathol.*, 2000, **157**, 423–433.
- 134 G. F. Souza, A. A. Calado, R. Delcelo, V. Ortiz and A. Macedo, Jr., *Int. Braz. J. Urol.*, 2008, **34**, 345–351; discussion 351–344.

